Clinical Microbiomics partners innovators in microbiome research across the pharma/biotech, consumer health, and academic spaces, becoming particularly known for its pioneering work on clonal-level microbiome profiling that is recognised as the most sensitive, precise, and comprehensive in the field.
Importantly, the seven-year-old company hosts the richest data-warehouse on the market with more than 30,000 samples linking more than 3 million bacterial strains to clinical phenotypes.
The investment, from Seventure’s Health for Life Capital II fund, will be used to further advance the company’s microbiome profiling and systems biology platform, and to expand the service offering within multi-omics data integration, as well as to build further presence across other key global markets starting with the US.
“Our vision is a world where people are healthier because we understand how to improve our inner ecology – the microbiome,” says Anders Grøn, CEO at Clinical Microbiomics, “We challenge the idea that the complexity of the microbiome prevents us from exploring its potential to tackle the most pressing health questions of our time.
“Seventure Partners brings valuable experience across the microbiome field that will help us identify and address challenges across the sector, and their investment will enable us to expand our innovation programs, quality management systems, and strategic collaborations at a high pace to help researchers worldwide to bring new products and treatments to market.”
The business is located in Medicon Valley, spanning eastern Denmark and southern Sweden, but its microbiome analysis services are offered worldwide to clients across sectors such as pharma, biotech, nutrition, food, feed, personal care, and consumer testing.
Isabelle de Cremoux, CEO and managing partner at Seventure Partners, added: “Incredible progress has been made in understanding the link between the microbiota and our health in the past years, but there is still much more to be accomplished.
“There is a lot of data available, but we need better tools to get more insights and standards for how to put it to practice. Clinical Microbiomics has a track-record of developing tools that can untangle the complexity of the microbiome and help researchers worldwide understand the mechanisms that impact health and disease.
“Our investment will enable Clinical Microbiomics to invest even further to lead the way with innovative concepts and services at pharma standards for this field, and we believe their work will play a critical role in unleashing the potential of microbiome science”.
